← Back to Screener
Cullinan Therapeutics, Inc. Common Stock (CGEM)
Price$14.52
Favorite Metrics
Price vs S&P 500 (26W)94.77%
Price vs S&P 500 (4W)8.72%
Market Capitalization$911.52M
All Metrics
Book Value / Share (Quarterly)$6.78
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.92
Price vs S&P 500 (YTD)41.37%
EPS (TTM)$-3.72
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$-3.72
EPS (Annual)$-3.11
ROI (Annual)-28.35%
Cash / Share (Quarterly)$6.27
ROA (Last FY)-26.92%
EBITD / Share (TTM)$-4.09
ROE (5Y Avg)-16.56%
Cash Flow / Share (Annual)$-2.92
P/B Ratio2.23x
P/B Ratio (Quarterly)1.50x
Net Income / Employee (Annual)$-2
ROA (TTM)-43.27%
EV / EBITDA (TTM)7.17x
EPS Incl Extra (Annual)$-3.11
Current Ratio (Annual)10.25x
Quick Ratio (Quarterly)10.01x
3-Month Avg Trading Volume0.86M
52-Week Price Return97.90%
EV / Free Cash Flow (Annual)-0.85x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10.96
P/S Ratio (Annual)48.13x
Asset Turnover (Annual)0.04x
52-Week High$16.74
EPS Excl Extra (Annual)$-3.11
CapEx CAGR (5Y)37.42%
26-Week Price Return103.51%
Quick Ratio (Annual)10.01x
13-Week Price Return38.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.25x
Enterprise Value$823.192
Book Value / Share Growth (5Y)7.14%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-356.34%
Cash / Share (Annual)$6.27
3-Month Return Std Dev58.85%
Net Income / Employee (TTM)$-2
ROE (Last FY)-28.35%
EPS Basic Excl Extra (Annual)$-3.11
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.72
ROI (TTM)-46.19%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$11.68
Price vs S&P 500 (52W)62.80%
Year-to-Date Return45.51%
5-Day Price Return5.68%
EPS Normalized (Annual)$-3.11
ROA (5Y Avg)-15.57%
Net Profit Margin (Annual)-346.20%
Month-to-Date Return5.98%
Cash Flow / Share (TTM)$-3.70
EBITD / Share (Annual)$-3.66
Operating Margin (Annual)-358.76%
ROI (5Y Avg)-16.56%
EPS Basic Excl Extra (TTM)$-3.72
P/TBV (Quarterly)0.80x
P/B Ratio (Annual)1.50x
Book Value / Share (Annual)$6.78
Price vs S&P 500 (13W)35.68%
Beta0.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-46.19%
52-Week Low$5.68
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.35
4.42
4.42
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CGEMCullinan Therapeutics, Inc. Common Stock | — | — | — | — | $14.52 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and oncology therapies. The company develops treatments that inhibit key disease drivers or harness the immune system to eliminate diseased cells in cancer and autoimmune indications. Its pipeline leverages differentiated expertise in translational medicine and immunology to address unmet needs across multiple therapeutic areas.